Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis

• Published in: Journal of rheumatology 2014-11, Vol.41 (11), p.2104-2113
• Main Authors: Maksymowych, Walter P, Naides, Stanley J, Bykerk, Vivian, Siminovitch, Katherine A, van Schaardenburg, Dirkjan, Boers, Maarten, Landewé, Robert, van der Heijde, Désirée, Tak, Paul-P, Genovese, Mark C, Weinblatt, Michael E, Keystone, Edward C, Zhukov, Olga S, Abolhosn, Rania W, Popov, Joanna M, Britsemmer, Karin, van Kuijk, Arno W, Marotta, Anthony
• Format: Article
• Language: English
• Subjects: 14-3-3 Proteins - blood; Adult; Area Under Curve; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - physiopathology; Biomarkers - blood; Canada; Case-Control Studies; Cohort Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay - methods; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Prognosis; Reference Values; Rheumatoid Factor - blood; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric
• ISSN: 0315-162X; 1499-2752
• DOI: 10.3899/jrheum.131446

Serum 14-3-3η is a novel joint-derived proinflammatory mediator implicated in the pathogenesis of rheumatoid arthritis (RA). In our study, we assessed the diagnostic utility of 14-3-3η and its association with standard clinical and serological measures. A quantitative ELISA was used to assess 14-3-3η levels. Early (n=99) and established patients with RA (n=135) were compared to all controls (n=385), including healthy subjects (n=189). The sensitivity, specificity, positive and negative predictive values of 14-3-3η, and the likelihood ratios (LR) for RA were determined through receiver-operator curve analysis. The incremental value of adding 14-3-3η to anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) in diagnosing early and established RA was assessed. Serum 14-3-3η differentiated established patients with RA from healthy individuals and all controls (p